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Obesity-related glomerulopathy is an increasing cause of end-stage renal disease. Obesity has been considered a state of chronic
low-grade systemic inﬂammation and chronic oxidative stress. Augmented inﬂammation in adipose and kidney tissues promotes
the progression of kidney damage in obesity. Adipose tissue, which is accumulated in obesity, is a key endocrine organ that
produces multiple biologically active molecules, including leptin, adiponectin, resistin, that aﬀect inﬂammation, and subsequent
deregulation of cell function in renal glomeruli that leads to pathological changes. Oxidative stress is also associated with obesity-
related renal diseases and may trigger the initiation or progression of renal damage in obesity. In this paper, we focus on
inﬂammation and oxidative stress in the progression of obesity-related glomerulopathy and possible interventions to prevent
kidney injury in obesity.
1.Introduction
Obesity has become a heavy public health problem in the
United States, with a prevalence among adults increasing to
32% from 13% between the 1960s and 2004 [1]. Currently,
66% of adults and 16% of children and adolescents are over-
weight or obese [1]. Although obesity has long been recog-
nized as an independent risk factor for cardiovascular dis-
eases and diabetes mellitus, newer research points to obesity
as an important risk factor for chronic kidney diseases
(CKDs) [2–4]. In 1974, Weisinger et al. [5] ﬁrstly reported
that massive obese patients developed nephrotic-range pro-
teinuria. Subsequent studies conﬁrmed that obesity could
induce renal injury, namely, obesity-related glomerulopathy
(ORG)[6–8].Alarge-scaleclinicopathologic studyincluding
6818 renal biopsies from 1986 to 2000 revealed a progressive
increaseinbiopsyincidenceofORGfrom0.2%in1986–1990
to 2.0% in 1996–2000 [8]. The tenfold increase in incidence
of ORG over 15 years suggests a newly emerging epidemic
[8].
The clinical characteristics of subjects with ORG typi-
cally manifest with nephrotic or subnephrotic proteinuria,
accompanied by renal insuﬃciency [8–10]. Histologically,
ORG presents as focal segmental glomerulosclerosis (FSGS)
and glomerular hypertrophy or glomerular hypertrophy
alone and relatively decreased podocyte density and number
and mild foot process fusion [8, 11, 12]. Clinically, it is
distinguished from idiopathic FSGS (I-FSGS) by its lower
incidence of nephrotic syndrome, more benign course, and
slower progression of proteinuria and renal failure [8, 11].
ORG is an increasing cause of end-stage renal disease
(ESRD). The pathophysiology of ORG remains incomplete-
ly understood. Potential mechanisms by which obesity af-
fects renal physiology include altered renal hemodynam-
ics, insulin resistance, hyperlipidemia, activation of renin-
angiotensin-aldosterone system (RAAS), inﬂammation, and
oxidative stress. Increases in both glomerular ﬁltration rate
(GFR) and renal plasma ﬂow (RPF) were observed in
obese subjects and animals [13, 14]. This likely occurs be-
cause of aﬀerent arteriolar dilation as a result of proximal
salt reabsorption, coupled with eﬀerent renal arteriolar vaso-
constriction as a result of elevated angiotensin II (AngII)
[15]. These eﬀects may contribute to hyperﬁltration, glom-
erulomegaly,andlaterfocalglomerulosclerosis[8,9].Insulin2 International Journal of Nephrology
resistance can raise the transcapillary pressure gradient and
cause hydrostatic pressure and hyperﬁltration by reducing
norepinephrine-inducedeﬀerentarteriolarconstriction[16],
leading to glomerular hypertrophy and sclerosis. Hyperin-
sulinemia also has been shown to stimulate the synthe-
sis of growth factors such as insulin-like growth factor-
(IGF-) 1 and IGF-2 and transforming growth factor-
β1(TGF-β1), which accelerate production of extracellular
matrix and promote glomerular hypertrophy and sclerosis
[17, 18]. Hyperlipidemia may promote glomerulosclerosis
throughmechanismsthatinvolveengagementoflow-density
lipoprotein receptors on mesangial cells, direct podocyte
toxicity, oxidative cellular injury, macrophage chemotaxis,
and increase renal expression of sterol regulatory element-
binding proteins (SREBP-1 and SREBP-2), resulting in the
renal accumulation of cholesterol and triglycerides and to-
gether with signiﬁcant renal increase of ﬁbrogenic cytokines
[19, 20]. Adipose tissue is the major source of the com-
ponents of RAAS. Obese subjects usually have increases
in plasma renin activity, angiotensinogen, angiotensin-con-
verting enzyme activity, and circulating AngII, which trigger
or promote renal damage by renal hemodynamic changes
and nonhemodynamic pathways such as hyperinsulinemia,
oxidative stress, and inﬂammation [21–23]. Inﬂammatory
abnormalities and oxidative stress are characteristic ﬁndings
of obesity and play important roles in the renal damage as-
sociated with obesity, which will be discussed in detail in the
following.
2. InﬂammationinObesity-Related
Glomerulopathy
Recentstudieshavedemonstratedthatobesitycauseschronic
low-grade systemic inﬂammation and thus contributes to
the development of systemic metabolic dysfunction that is
associated with obesity-related disorders and renal disease
[24–27].Levelsofsomeinﬂammatorymarkersandcytokines
such as C-reactive protein (CRP), tumor necrosis factor-α
(TNF-α), interleukin-6 (IL-6), and macrophage migration
inhibitory factor (MIF) are elevated, whereas concentra-
tions of adiponectin, a protein hormone that exerts anti-
inﬂammatory activities, are reduced in obesity [28–34].
2.1. Leptin. Leptin is a 16-kDa-peptide hormone encoded by
obese (ob) gene that is mainly produced by adipose tissue.
Leptin serves as a regulator of energy balance by binding to
the full-length leptin receptors—obese receptor b (Ob-Rb)
in the hypothalamus, leading to reduction in food intake
and elevation in temperature and energy expenditure [35].
L e p t i nr e c e p t o r sc a nb ec l a s s i ﬁ e da ss e c r e t e d - f o r m s( O b - R e ) ,
short-forms (ob-Ra, c, d, and f) mainly expressed in periph-
eraltissue,andlong-forms(ob-Rb)predominantlyexpressed
in hypothalamus. The kidney expresses abundant concentra-
tions of the truncated isoform of the leptin receptor Ob-
Ra, but only a small amount of the full-length receptor
Ob-Rb [36]. Leptin production is associated with increased
size of adipocytes and is positively correlated with the
body mass index (BMI) [37]. Increased circulating leptin, a
marker of leptin resistance, is common in obesity. Obesity-
inducedleptinresistanceinjuresnumerousperipheraltissues
including kidney, liver, myocardium, and vasculature [36,
38]. Leptin results in the development of renal disease by
binding to its speciﬁc receptors in renal endothelial cells and
mesangial cells. In glomerular endothelial cells, leptin stimu-
latescellularproliferation,TGF-β1 synthesis,andtypeIVcol-
lagen production [36, 39]. In mesangial cells, leptin upregu-
lates synthesis of the TGF-β type II receptor, but not TGF-
β1, and stimulates glucose transport and type I collagen pro-
duction through signal transduction pathways involving
phosphatidylinositol-3-kinase [40]. Leptin also stimulates
hypertrophy, but not proliferation in cultured rat mesangial
cells [41]. However, both those cell types increase their ex-
pression of extracellular matrix in response to leptin. Trans-
genic mice with leptin overexpression demonstrated an in-
crease in collagen type IV and ﬁbronectin mRNA in the
kidney [41]. Leptin is involved in the development of
glomerulosclerosis through a paracrine TGF-β pathway (be-
tween glomerular endothelial and mesangial cells) that pro-
motes the deposition of extracellular matrix, proteinuria,
and, eventually, glomerulosclerosis [39]. Infusion of leptin
into normal rats for 3 weeks fosters the development of focal
glomerulosclerosis and proteinuria [36].
Leptin also has proinﬂammatory actions through its
interaction with mediators of innate and adaptive immunity
and CRP [38]. Leptin regulates components of innate and
adaptive immunity, including T lymphocytes and mono-
cytes/macrophages [42, 43]. Central leptin administration
in ob/ob mice accelerates renal macrophage inﬁltration
through the melanocortin system [44]. Leptin stimulates
central T-cell production and a peripheral shift in favor of
T helper (Th) 1 adaptive immune responses (proinﬂamma-
tory) as opposed to Th2 responses (anti-inﬂammatory) [38].
Leptin has been shown to modulate adaptive immunity by
enhancingT-cellsurvivalandstimulatingproductionofpro-
inﬂammatory cytokines such as IFN-γ and IL-2 [45]. Leptin
also has structural and functional resemblance to proinﬂam-
matory cytokines, such as IL-6 [42], and may modulate CRP,
a leptin-interacting protein [46].
Therefore, these direct and indirect eﬀects of leptin on
the kidney, including stimulating cellular proliferation and
hypertrophy, increasing extracellular matrix expression, and
exhibiting proinﬂammatory activities, may partially explain
obesity-related kidney disease.
2.2. Adiponectin. Adiponectin is a 30 kDa adipocyte-derived
protein hormone encoded by the adipose most abundant
gene transcript 1 (APM1), [47] which plays a role in the
suppressionofinﬂammation-associatedmetabolicdisorders.
Two distinct adiponectin receptors, AdipoR1 and R2, have
been cloned [48]. AdipoR1 is expressed ubiquitously while
AdipoR2 is most abundant in the liver. Adiponectin is highly
abundant in human serum, but its level is decreased in
most obese animal and human subjects, particularly in those
with visceral obesity [49–51]. Recent clinical studies show a
negative association of adiponectin in obese patients, [52,
53] suggesting that adiponectin may play a key role in theInternational Journal of Nephrology 3
development of obesity-related albuminuria and alteration
of renal function.
Studies with the adiponectin knockout mouse provide
evidence that adiponectin can regulate podocyte function
and thus contribute to the initial development of albumin-
uria [37, 53]. Sharma et al. showed that knockout of adipo-
nectin in mice increased albuminuria and caused fusion
of podocyte foot processes [53]. In cell culture studies
with podocytes, incubation with adiponectin potently de-
creased permeability to albumin, induced translocation of
zona occludens-1 (ZO-1) to the plasma membrane, and re-
duced the renal predominant NADPH oxidase Nox 4,
largely via a 5 -AMP-activated-protein kinase- (AMPK-)
dependent pathway. Treatment of the adiponectin knockout
mice with exogenous adiponectin was able to decrease albu-
minuria and improve podocyte morphology [53]. Chronic
hyperadiponectinemia signiﬁcantly alleviated the progres-
sion of proteinuria in early-stage diabetic nephropathy by
several mechanisms. It led to an increase in nephrin expres-
sion, improvement of the endothelial dysfunction due to
decreases in endothelin 1 (ET-1) and plasminogen activator
inhibitor 1 (PAI-1), and an increase in endothelial nitric
oxide synthase (eNOS) expression in the renal cortex [54].
Recent studies suggest that adiponectin exerts anti-in-
ﬂammatoryeﬀectsbysuppressingTNF-α-inducedactivation
of nuclear factor-κB( N F - κB) in human aortic endothelial
cells and aortic smooth muscle cells through inhibition of
IκB phosphorylation [55, 56] and inhibition of vascular cell
adhesion molecule 1 (VCAM-1) and intercellular adhesion
molecule 1 (ICAM-1) expression [57], thereby reducing mo-
nocyte adhesion and macrophage-induced cytokine produc-
tion [58] and CRP expression in human adipose tissue [59].
Human adipose tissue expressed CRP, which was negatively
correlatedwithadiponectinexpressioninadiposetissue[59].
Low levels of adiponectin are associated with higher levels
of highly-sensitive C-reactive protein (hs-CRP) and IL-6
[49], two inﬂammatory mediators that are involved in the
initiation and progression of atherosclerosis and renal dis-
ease. Therefore, hypoadiponectinemia contributes to devel-
opment of a low-grade systemic chronic inﬂammation state,
suggesting that hypoadiponectinemia may play a causative
role in the systemic and vascular inﬂammation commonly
found in obesity and obesity-related disorders, including re-
nal injury, through its proinﬂammatory eﬀects.
2.3. Resistin. Resistin, also known as adipocyte-speciﬁc
secretory factor (ADSF) or as found in inﬂammatory zone
(Fizz), is a cysteine-rich 12.5-kDa polypeptide that belongs
to a small family called resistin-like molecules (RELMs) [60,
61].Inrodents,resistinissecretedfromwhiteadipocytes[62,
63]. In human, it is produced largely by macrophages and
expressed in adipose tissue predominantly by nonadipocyte
resident inﬂammatory cells [64–66]. Current evidence sug-
gests that resistin has been variably associated with obesity,
insulin resistance, inﬂammation, and renal dysfunction.
Resistin levels are elevated in both genetic and diet-induced
animal models of obesity [62, 67]. Studies of obese subjects
have frequently noted higher serum levels of resistin as well
as direct correlations between resistin level and adiposity as
measured by BMI [68, 69]. There has been a link between
circulating resistin and low-grade inﬂammation that accom-
pany obesity [70]. Resistin is associated with elevated CRP
and white blood cells, suggesting that the role of resistin
may be a component of obesity-related inﬂammation [70].
It has recently been found that resistin involves in the
regulation of proinﬂammatory cytokine expression. Resistin
strongly upregulates IL-6 and TNF-α in human peripheral
blood mononuclear cells (PBMCs) via NF-κBp a t h w a y[ 71].
Human resistin enhanced secretion of proinﬂammatory cy-
tokines, TNF-α and IL-12 in macrophages by NF-κB-de-
pendentpathway[72].Studiesalsoshowthatincreasedlevels
of resistin in patients with CKD are associated with declined
renal function and inﬂammation [73, 74]. This suggests that
resistinmayplayanimportantroleinobesityandobesity-as-
sociated disease by triggering the release of other proinﬂam-
matory cytokines.
2.4. Inﬂammatory Markers. A growing body of evidence in-
dicates that obesity-related glomerulopathy is associated
with upregulation of inﬂammatory mediators [75]. Obesity
leads to adipose tissue macrophage inﬁltration in white adi-
pose tissue and increased levels in proinﬂammatory cyto-
kines. Several inﬂammatory mediators released from adipo-
cytes and macrophages, such as TNF-α,I L - 6 ,I L - 1 β,C R P ,
monocyte chemoattractant protein 1 (MCP-1), PAI-1, and
MIF, contribute to a low level of chronic inﬂammatory state
in obesity and may be responsible for renal injury in obesity-
associated glomerulopathy. An emerging pattern of gene
expression was observed in adipose tissue in mice fed high
fat-fed diets, indicating a shift toward global upregulation
of inﬂammatory genes, including TNF-α,I L - 6 ,a n dM C P - 1
[76].
TNF-α, a proinﬂammatory cytokine, is predominantly
produced by macrophages inﬁltrating adipose tissue [77, 78]
and can also be produced by the kidney [79]. This cytokine
is involved in the genesis of inﬂammation and contributes
to obesity-associated insulin resistance [80–82]. Within the
kidney,AngII,advancedglycationend-products(AGEs),and
oxidized low-density lipoprotein (LDL)canstimulate TNF-α
synthesis from renal cells to initiate local damage [83–86]. A
recentstudydemonstratesthatTNF-αreducestheexpression
of Klotho, a protein expressed by renal cells, through an NF-
κB-dependent mechanism, which contribute to renal injury
[87]. TNF-α enhances the expression of PAI-1 in human adi-
pose tissue and plasma PAI-1 levels in obesity subjects and
is responsible for reduced ﬁbrinolysis and also a component
of extracellular matrix, leading to renal ﬁbrosis and terminal
renal failure [88–90]. TNF-α also has been shown to induce
the expression of MCP-1 via p38 mitogen-activated protein
kinase (MAPK) signaling pathway in renal mesangial cells
[91]. MCP-1, a key regulator in recruiting monocytes to the
glomeruli, may also contribute to renal damage at a later
stage of kidney disease in obesity.
IL-6 is another important proinﬂammatory mediator
systemically secreted from adipose tissue and locally pro-
duced in the kidney. Studies have demonstrated the positive
relationship between BMI and plasma IL-6 concentrations
[92–94]. Studies also suggest that IL-6 plays a key role in4 International Journal of Nephrology
the development of renal disease. Endogenous IL-6 enhances
the degree of renal injury, dysfunction, and inﬂammation
caused by ischemia/reperfusion by promoting the expression
of adhesion molecules and subsequent oxidative stress [95].
Transgenic knockout of IL-6 ameliorates renal injury as
measured by serum creatinine and histology [96]. Blocking
the IL-6 receptor prevents progression of proteinuria and
renal lipid deposit as well as the mesangial cell proliferation
associated with severe hyperlipoproteinemia [97]. IL-6 also
stimulates the synthesis of CRP [98], which is well known as
both a marker and important risk factor of atherosclerosis in
the general population and CKD patients [99].
MIF was initially described as an immunomodulatory
factor isolated from the supernatants of T lymphocytes and
was found to inhibit the random migration of macrophages
[100]. Subsequent studies have indicated that MIF acts as
a proinﬂammatory cytokine and pituitary-derived hormone
that potentiates endotoxemia [101]. MIF also plays a path-
ogenic role in kidney disease. In a rat model of immuno-
logically induced crescentic antiglomerular basement mem-
brane glomerulonephritis, treatment with anti-MIF anti-
body reduced proteinuria, prevented the loss of renal func-
tion, attenuated histological damage including glomerular
crescent formation, inhibited renal leukocytic inﬁltration
and activation, and reduced IL-1β expression by both intrin-
sic kidney cells and macrophages [102]. Thus, MIF is a key
mediator of the inﬂammatory and immune response and
plays a pathological role in immune-mediated renal injury.
3. OxidativeStressin
Obesity-RelatedGlomerulopathy
3.1. Obesity and Oxidative Stress. Oxidative stress is caused
by an imbalance between increased production of reactive
oxygen species (ROS) and/or reduced antioxidant activity,
leading to oxidative damage to cells or tissue including lip-
ids, proteins and DNA. It is known that oxidative stress is
involved in pathological processes of various diseases, such
ascancer,diabetesmellitus,hypertension,andcardiovascular
disease. Studies have suggested that obesity is associated with
increased oxidative stress [103, 104]. Analysis of oxidative
markers in obesity subjects indicates that oxidative damage
is associated with increased BMI and percentage of body fat
[105, 106]. Conversely, parameters of antioxidant capacity
are inversely related to the amount of body fat and central
obesity [107, 108]. The possible mechanisms of obesity-
related oxidative stress include increased oxygen consump-
tion and subsequent production of free radicals derived
from the increase in mitochondrial respiration, diminished
antioxidant capacity, fatty acid oxidation, lipid oxidizability,
and cell injury causing increased rates of free radical form-
ation [104, 109, 110]. It is also reported that the increase
in obesity-associated oxidative stress is due to the presence
of excessive adipose tissue accumulation [111]. Accumulated
adipose tissue generates an immune response leading to the
secretion of proinﬂammatory cytokines, including TNF-α,
IL-1, and IL-6, which lead to increased generation of ROS.
Excessive fat accumulation also stimulates nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity,
which contributes to ROS production [112]. ROS, in return,
augmented the expressions of NADPH oxidase (NOX) sub-
units,includingNOX4andPU.1inadipocytes,establishinga
vicious cycle that augments oxidative stress in white adipose
tissue and blood [112].
3.2. Oxidative Stress and Inﬂammation. Oxidative stress in
adipocyte seems to be responsible for the low-grade proin-
ﬂammatory state commonly observed in obesity [113, 114].
Oxidative stress is increasingly viewed as a major upstream
component in cell-signaling cascades involved in inﬂamma-
tory responses, stimulating the expression of proinﬂamma-
tory cytokines. ROS activate redox-sensitive transcription
factors, particularly NF-κB, inducing the release of proin-
ﬂammatory cytokines and the expression of adhesion mole-
culesandgrowthfactors,includingTNF-α,IL-6,IL-1β,T GF -
β1, connective tissue growth factor, IGF-1, platelet-derived
growth factor, and VCAM-1 [115, 116]. H2O2 stimulates IL-
4 and IL-6 gene expression and cytokine secretion by an
apurinic/apyrimidinic-endonuclease/redox-factor-1- (APE/
Ref-1-) dependent pathway [117]. ROS increased the expres-
sion levels of PAI-1, IL-6, and MCP-1 through NADPH
oxidase pathway [112]. Oxidized high-density lipoprotein
(HDL) enhances proinﬂammatory properties such as TNF-
α and MCP-1 in renal mesangial cells partly via CD36
and LDL receptor-1 and via MAPK and NF-κBp a t h w a y s
[118]. Oxidized LDL can stimulate TNF-α synthesis from
renal cells and initiate local eﬀects of renal damage [85].
Increased ROS production and MCP-1 secretion from
accumulated fat may cause inﬁltration of macrophages and
inﬂammation in adipose tissue of obesity [112]. Moreover,
enhanced macrophage migration induces the release of
proinﬂammatory cytokines, which further stimulates the
generation of ROS [119, 120]. Therefore, oxidative stress-
induced cytokine production is likely to further increase
oxidative stress levels, setting a vicious cycle [121] that may
promote the progression of kidney damage in obesity.
3.3. Oxidative Stress Leads to Renal Injury in Obesity. Oxida-
tive stress has been commonly identiﬁed in obesity-related
renal diseases and may be the mechanism underlying the
initiation or progression of renal injury in obesity [122, 123].
Previous studies suggest that oxidative stress triggers, at an
early age, the onset of kidney lesions and functional im-
pairment in Zucker obese (ZO) fa/fa rats, a good model of
obesity-related renal disease, in absence of hyperglycaemia,
hypertension, and inﬂammation [124]. ROS play a crucial
role in mediating renal injury [125–127]. ROS are highly
reactivemoleculesthatoxidizelipidsandproteins,causecell-
ular injury, and promote glomerular and renal tubule injury
and associated proteinuria [128].
ROS are produced by various cells, such as vascular
cells, inﬂammatory cells, and renal cells, and have distinct
function on diﬀerent types of cells, such as endothelial dys-
function, inﬂammatory gene expression, and renal tubule
ion transport. A major source for vascular and renal ROS is a
Nox family of nonphagocytic NAD(P)H oxidases, including
the prototypic Nox2 homolog-based NAD(P)H oxidase, asInternational Journal of Nephrology 5
well as other NAD(P)H oxidases, such as Nox1 and Nox4
[129]. Numerous reports indicate that within the kidney,
NAD(P)H oxidase, an enzyme that produces superoxide
(O2
•−) by transferring electrons from NADH/NADPH to
molecular oxygen and thereby forming O2
−,H +,a n d
NAD+/NADP+, is capable of modulating renal epithelial ion
transport [130, 131]. NAP(D)H oxidase-derived ROS can
alter renal pressure natriuresis and blood pressure regulation
through its eﬀects on renal hemodynamics and renal tubular
sodium transport. Recent data suggest that NADPH oxidase-
mediated oxidative injury to the proximal tubule, like that
seen in the glomerulus, contributes to proteinuria in insulin-
resistant states [128].
Oxidative stress also plays an important role in the path-
ogenesis of renal damage through its eﬀects on vascular bio-
logy. ROS are generated by all types of vascular cells, in-
cluding endothelial, smooth muscle, and adventitial cells.
ROS inﬂuence vascular cell growth, migration, proliferation,
and activation [132, 133]. Physiologically, ROS can mediate
cellular function, receptor signals, and immune responses
on vascular cells. In pathophysiological condition, ROS con-
tribute to progressive vascular dysfunction and remodel-
ing through oxidative damage caused by decreased nitric
oxide (NO) bioavailability, impaired endothelium-depend-
ent vasodilatation and endothelial cell growth, apoptosis or
anoikis, endothelial cell migration, and activation of adhe-
sion molecules and inﬂammatory reactions [134, 135].
4. PotentialInterventionsto
Prevent Renal Injury
4.1.Anti-InﬂammationTherapy. Obesityacceleratesthepro-
gression of renal injury, associated with augmented inﬂam-
mation in adipose and kidney tissues [136]. Anti-inﬂam-
mation therapy might be a potential treatment for renal
damage. IL-6 is a key inﬂammatory molecule in renal
diseases. Studies in IL-6 transgenic mice suggested that high
concentrationsofIL-6contributetodevelopmentofrenalin-
jury [137]. Treatment with anti-IL-6 receptor antibody
MR16-1 prevented progression of proteinuria, renal lipid
deposit, and the mesangial cell proliferation in hypercho-
lesterolemia-induced renal injury [97]. TNF-α is another
important proinﬂammatory cytokine in the development of
renal diseases. Inhibition of TNF-α by etanercept, a TNF-
α antagonist, also decreased blood pressure and protected
the kidney through reduction of renal NF-κB, oxidative
stress, and inﬂammation [138]. TNF-α blockade increases
renal Cyp2c23 expression and slows the progression of renal
damage in salt-sensitive hypertension [139]. TNF-α inhibi-
tionalsoreducesrenalinjuryindeoxycorticosterone-acetate-
(DOCA-) salt hypertensive rats via suppression of renal cor-
tical NF-κBa c t i v i t y[ 140]. Adiponectin is an adipose-secret-
ed hormone with anti-inﬂammatory properties. Treatment
of adiponectin-knockout mice with adenovirus-mediated
adiponectin results in amelioration of albuminuria, glom-
erular hypertrophy, and tubulointerstitial ﬁbrosis and redu-
ces the elevated levels of VCAM-1, MCP-1, TNF-α,T G F - β1,
collagen type I/III, and NADPH oxidase components [141].
Adiponectin prevents glomerular and tubulointerstitial
injury through modulating inﬂammation and oxidative
stress [141].
Excessive fat accumulation contributes to macrophage
inﬁltration in adipose tissue and increased production of
proinﬂammatory cytokines, such as TNF-α,I L - 8 ,a n dI L -
6[ 142–145]. Consequently, it is possible that weight loss
maybeapotentialmethodtoreduceinﬂammation.Evidence
indicatesthatweightlossinducedbynutritionalintervention
or gastric surgery markedly improves the systemic and adi-
pose tissue inﬂammatory states linked to obesity [143, 146,
147]. Studies by gene proﬁling analysis have shown that
caloric restriction-induced weight reduction leads to the reg-
ulation of a wide variety of inﬂammation-related molecules
inhumanadiposetissue[148].Weightlossgloballyimproves
the inﬂammatory proﬁle of obese subjects through a de-
crease of proinﬂammatory factors and an increase of anti-
inﬂammatorymoleculesinwhiteadiposetissue[148].Roux-
en-Y-Gastric-Bypass- (RYGB-) induced weight loss has been
shown to reduce MCP-1, IL-18, IL-6, and TNF-α concentra-
tions [149, 150]. A longer-term weight reduction induced by
RYGB in corpulence also prevails in regulating circulating
cytokine concentrations [151]. Weight loss also ameliorates
the low-grade inﬂammation state that leads to glomerular
dysfunction in obesity. In morbidly obese individuals with
glomerular hyperﬁltration, weight loss by surgical inter-
ventions normalizes glomerular ﬁltration rate (GFR) and
reduces blood pressure and microalbuminuria [152]. Weight
loss improves renal function as shown by reduced levels of
serum creatinine and improved creatinine clearance [153].
4.2. Antioxidant Intervention. Since ROS play a key role in
the pathogenesis of renal injury such as glomerulosclerosis
andtubulointerstitialﬁbrosis,approachestoreduceoxidative
stress by antioxidants supplementation, nutritional and sur-
gical interventions may have renoprotective eﬀects. Garcinia
protects against obesity-induced nephropathy by attenuating
oxidativestressthroughreducedlipidperoxidationandlevels
of oxidized LDL [154] .T h eo b e s eZ u c k e rr a ti sag o o d
model for studying obesity-related kidney disease because it
develops proteinuria, glomerular hypertrophy, and focal seg-
mental glomerulosclerosis [155–157]. Using these rats, it has
been demonstrated that nephropathy is associated with oxi-
dative stress, and supplementation with an antioxidant
ebselen improved kidney damage by ameliorating protein-
uria and renal focal and segmental sclerosis [158]. Chronic
ebselen therapy also improved vasculopathy with lipid
deposits,tubulointerstitialscarring,andinﬂammation[158].
Other antioxidants also have renoprotective eﬀects. For ex-
ample, administration of grape seed proanthocyanidin ex-
tract (GSPE), an eﬃcient phytochemical antioxidant, can
protectagainstthenephrotoxicityeﬀectsinducedbycisplatin
a n dg e n t a m i c i n[ 159, 160] and reverse experimental myo-
globinuric acute renal failure [161]. Quercetin, a ﬂavonoid
that exhibits antioxidant properties in many diseases, could
also protect the rat kidney against lead-induced injury and
improve renal function [162]. Thus, antioxidants may be a
potential therapeutic to prevent the renal damage in ORG.
Nutritional and surgical interventions are additional ap-
proaches to reduce oxidative stress and prevent kidney injury6 International Journal of Nephrology
in obesity. Caloric restriction and protein restriction reduce
free radicals and ROS formation and inhibit accumulation
of oxidative biomarkers in animal models [163]. In geneti-
cally obese animals, diet restriction can prevent or greatly
delay the onset of speciﬁc degenerative lesions, in particular
glomerulonephritis associated with obesity [164]. Since
adipose tissue mass in obesity contributes to oxidative stress,
bariatric surgery-induced weight loss also results in decreas-
ing systemic oxidative stress in adiposity [111]. Weight loss
induced by diet restriction or bariatric surgery not only im-
proves inﬂammation state but also reduces oxidative stress
state in obesity, which may protect renal function in obesity-
related glomerulopathy.
5. Conclusion
Obesity causes chronic low-grade inﬂammation and sys-
temic and local oxidative stress, which may play a pivotal role
in the initiation or progression of obesity-associated glomer-
ulopathy. Elevated inﬂammation in obesity is the result of
the production of adipokines and increased inﬂammatory
cytokines and decreased anti-inﬂammatory factors. Oxida-
tive stress is triggered by an imbalance between increased
productionofROSand/orreducedantioxidant activity.Both
inﬂammation and oxidative stress induce damage to renal
tubule and glomerulus and result in endothelial dysfunction
in the kidney. Therefore, anti-inﬂammation and antioxidant
interventions may be the potential therapies to prevent and
treat obesity-related renal diseases.
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